# Cencora Inc. (COR) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Health Care Providers. Price $340.50, market value $65.0 billion.

## Valuation
- **P/E (trailing): 25.3×** (5-yr avg 24.1×, 3-yr avg 29.7×). Cencora Inc. trades at 25.3× trailing earnings, close to its own five-year average of 24.1×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 3.02**. A PEG of 3.02 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 0.2×**. Each dollar of revenue is priced at 0.2×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 21.3×**. The shares trade at 21.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 6.2%** (5-yr avg 7.8%). Free cash flow equals 6.2% of the market value, below its five-year average of 7.8%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 4.0%**. The inverse of the P/E: 4.0% of the price is earned each year.

## Profitability
- **Gross margin: 4.0%**. Cencora Inc. keeps 4.0% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: 0.9%**. 0.9% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.5%**. 0.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 103.1%**. A 103.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 49.9%**. Return on all capital, debt included, is 49.9%: comfortably above what that capital costs.
- **Return on assets: 3.4%**. Each dollar of assets produces 3.4% of profit.

## Growth
- **Revenue growth (1 yr): 9.3%** (3-yr 10.4%/yr, 5-yr 11.1%/yr). Revenue grew 9.3% over the last year, against 11.1% a year compounded over five years.
- **EPS growth (1 yr): 5.7%** (3-yr -0.3%/yr). Earnings per share rose 5.7%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 13.3%/yr**. Free cash flow has compounded at 13.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 5.08**. Debt is 5.08 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 0.90** (quick 0.90). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.70%** ($2.35 per share, trailing). Cencora Inc. yields 0.70%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 28%** (12% of free cash flow). 28% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 3**. 3 straight years of increases.
- **Dividend growth (5 yr): -19.3%/yr** (1-yr 8.2%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover Cencora Inc.; the consensus is buy, with an average price target of $371.67 (+9% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 0.6%** (YTD 0.4%, 3-mo 9.6%). The shares are up 0.6% over twelve months including dividends.
- **From 52-week high: -9.8%** (39.1% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): -0.15** (volatility 31%). Beta of -0.15 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=COR · Page: https://foliofundamentals.com/stocks/cor

Not investment advice.